VIR
Vir Biotechnology Inc
11.50$
-0.7%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | |
| 5,497.0% | 633.6% | 174.8% | 3,420.0% | 8,202.9% | 717.5% | 3,879.1% | 8,032.9% | 63,105.0% | -572.1% | – | 0.0% | -70.0% | |
| -5,397.0% | -533.6% | -74.8% | -3,320.0% | -8,102.9% | -617.5% | -3,779.1% | -7,932.9% | -63,005.0% | 672.1% | – | 100.0% | 170.0% | |
| 5,495.6% | 649.1% | 177.6% | 3,418.3% | 8,200.8% | 857.3% | 3,913.1% | 8,032.0% | 63,109.6% | 137.9% | – | 56.6% | 159.6% | |
| 1,556.7% | 256.7% | 64.3% | 984.2% | 1,081.7% | 215.8% | 789.7% | 1,835.5% | 9,262.9% | 36.9% | – | 12.6% | 32.8% | |
| 1,678.9% | 294.5% | 67.3% | 1,838.7% | 1,615.8% | 329.2% | 823.4% | 1,821.3% | 9,262.9% | 729.3% | – | 69.3% | 259.0% | |
| -7,075.9% | -828.1% | -142.0% | -5,158.7% | -9,718.7% | -946.7% | -4,602.5% | -9,754.3% | -72,267.9% | -57.1% | – | 30.7% | -89.0% | |
| – | 1.4% | – | – | – | – | – | – | – | – | – | – | – | |
| -6,314.0% | -719.3% | -115.3% | -4,549.3% | -8,972.3% | -845.9% | -3,989.1% | -9,125.9% | -67,905.4% | -67.2% | – | 33.6% | -82.9% | |
| -121.8% | -28.5% | 0.5% | -49.2% | 7.4% | -0.7% | 0.5% | 14.0% | 70.0% | -0.2% | – | 0.1% | 0.1% | |
| -6,192.2% | -690.9% | -115.8% | -4,500.1% | -8,979.7% | -845.2% | -3,989.6% | -9,139.9% | -67,975.4% | -67.0% | – | 33.5% | -83.0% | |
| -6,774.3% | -752.5% | -131.2% | -4,165.7% | -9,062.9% | -810.0% | -4,474.3% | -9,528.2% | -66,656.3% | -62.7% | – | 32.8% | -80.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.